WallStSmart

Astrana Health Inc (ASTH)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 329% more annual revenue ($13.64B vs $3.18B). ASTH leads profitability with a 71.0% profit margin vs 5.5%. DVA trades at a lower P/E of 16.1x. DVA earns a higher WallStSmart Score of 66/100 (B-).

ASTH

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 6.0Value: 3.0Quality: 5.0

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASTHSignificantly Overvalued (-508.0%)

Margin of Safety

-508.0%

Fair Value

$3.13

Current Price

$24.48

$21.35 premium

UndervaluedFair: $3.13Overvalued
DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH3 strengths · Avg: 9.3/10
Profit MarginProfitability
71.0%10/10

Keeps 71 of every $100 in revenue as profit

Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

Areas to Watch

ASTH4 concerns · Avg: 2.8/10
Market CapQuality
$1.36B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

P/E RatioValuation
53.2x2/10

Premium valuation, high expectations priced in

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 71.0% and operating margin at 1.9%. Revenue growth of 42.9% demonstrates continued momentum.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Operating Margin. A P/E of 53.2x leaves little room for execution misses.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

ASTH profiles as a growth stock while DVA is a value play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.93 — expect wider price swings.

ASTH is growing revenue faster at 42.9% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (66/100 vs 46/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?